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Abstract
Background: Convection-enhanced delivery (CED), a direct method for drug delivery to the brain through
intraparenchymal microcatheters, is a promising strategy for intracerebral pharmacological therapy. By establishing
a pressure gradient at the tip of the catheter, drugs can be delivered in uniform concentration throughout a large
volume of interstitial fluid. However, the variables affecting perivascular distribution of drugs delivered by CED are
not fully understood. The aim of this study was to determine whether the perivascular distribution of solutes
delivered by CED into the striatum of rats is affected by the molecular weight of the infused agent, by co-infusion
of vasodilator, alteration of infusion rates or use of a ramping regime. We also wanted to make a preliminary
comparison of the distribution of solutes with that of nanoparticles.
Methods: We analysed the perivascular distribution of 4, 10, 20, 70, 150 kDa fluorescein-labelled dextran and
fluorescent nanoparticles at 10 min and 3 h following CED into rat striatum. We investigated the effect of local
vasodilatation, slow infusion rates and ramping on the perivascular distribution of solutes. Co-localisation with
perivascular basement membranes and vascular endothelial cells was identified by immunohistochemistry. The
uptake of infusates by perivascular macrophages was quantified using stereological methods.
Results: Widespread perivascular distribution and macrophage uptake of fluorescein-labelled dextran was visible 10
min after cessation of CED irrespective of molecular weight. However, a significantly higher proportion of
perivascular macrophages had taken up 4, 10 and 20 kDa fluorescein-labelled dextran than 150 kDa dextran (p <
0.05, ANOVA). Co-infusion with vasodilator, slow infusion rates and use of a ramping regime did not alter the
perivascular distribution. CED of fluorescent nanoparticles indicated that particles co-localise with perivascular
basement membranes throughout the striatum but, unlike soluble dextrans, are not taken up by perivascular
macrophages after 3 h.
Conclusions: This study suggests that widespread perivascular distribution and interaction with perivascular
macrophages is likely to be an inevitable consequence of CED of solutes. The potential consequences of
perivascular distribution of therapeutic agents, and in particular cytotoxic chemotherapies, delivered by CED must
be carefully considered to ensure safe and effective translation to clinical trials.
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Background
One of the major obstacles to the effective treatment of
neurological disorders ranging from brain tumours to
neurodegenerative diseases is the blood-brain barrier
(BBB), which regulates the passage of molecules from
the circulation into the central nervous system. Increas-
ing the dose of systemically administered therapeutics
has the potential to increase intracerebral drug delivery.
However, in the case of drugs such as chemotherapies,
this strategy risks increased systemic side-effects which
cannot be tolerated by patients. Consequently, there has
been considerable neurosurgical interest in developing
methods of direct interstitial drug delivery to the brain
in order to bypass the BBB.
Traditionally, intracerebral drug injection techniques
rely on diffusion of the therapeutic agent from the site
of introduction, significantly limiting the volume of dis-
tribution [1]. Furthermore, the clinical utility of intracer-
ebral drug injection may be hampered by tissue damage
associated with insertion of cannulae for drug delivery
[2]. Convection-enhanced delivery (CED) has emerged
as an alternative strategy for intracerebral drug delivery
using intraparenchymal microcatheters and has shown
significant potential in clinical trials [3,4]. By establish-
ing a pressure gradient at the tip of a very fine catheter,
drugs can be delivered in uniform concentration
through a much larger volume of interstitial fluid. CED
confers several potential advantages over conventional
intracerebral injection methods, including the distribu-
tion of therapeutic agents throughout large and clini-
cally-relevant brain volumes and avoidance of excess
tissue damage. Since the concept of pressure-mediated
interstitial drug delivery was first described in 1994 by
Bobo et al. [5], pre-clinical researchers have focused on
maximising the volume of drug distribution. It is now
clear that the ability to achieve widespread, predictable
and reproducible CED without reflux of infusate, is fun-
damentally reliant on a range of factors including cathe-
ter design, and the physicochemical properties and
tissue affinity of the infused agent [2,6-8].
In 2005 Krauze et al. [9] reported that CED of lipo-
somes into the putamen of non-human primates caused
the liposomes to be distributed within perivascular
spaces along branches of the lateral striate and middle
cerebral arteries. The authors suggested that the perivas-
cular pathways of the brain might serve as a conduit not
only for endogenous molecules (as had been proposed
by Szentistvanyi, Weller and others), but also intersti-
tially infused agents [10-12]. A number of studies have
demonstrated that tracers injected into the brain par-
enchyma drain along perivascular spaces in grey matter
and the subarachnoid space [11,13,14]. The unidirec-
tional nature and rapidity of solute transport appeared
to be driven by arterial pulsations, and perivascular dis-
tribution of solutes has been shown to be absent follow-
ing cardiac arrest [15]. Furthermore the interstitial
distribution of therapeutic molecules delivered by CED
is significantly restricted by hypotension, consistent with
a “perivascular pump” driven by arterial pulsations [16].
Mathematical modelling suggests that the effective peri-
vascular elimination of soluble metabolites and waste
products from the brain is fundamentally reliant on the
expansile nature of the arterial wall [17,18]. Conse-
quently, the stiffening of arteries which occurs with age-
ing may be a contributing factor to the failure of Ab
elimination seen in cerebral amyloid angiopathy and
Alzheimer’s disease [19,20].
Recent analysis of the perivascular pathways of the
brain suggests that the perivascular drainage pathway
for solutes is distinct from that of particulate materials.
Carare et al. [15] compared the perivascular drainage of
solutes with fluorescent particles injected into the cor-
pus striatum of mice and demonstrated that whilst solu-
ble infusates drained along perivascular basement
membranes, particulate infusates expanded a potential
space between the glia limitans and outer basement
membranes of striatal vessels. Particulate infusates were
ingested by resident perivascular macrophages, which
have wide ranging roles in the initiation, regulation and
propagation of neuroinflammatory processes [21-23].
A number of clinical trials of CED of soluble therapeu-
tic agents have been reported in recent years, including
chemotherapies for malignant glioma (topotecan, traber-
dersan, nimustine) and glial cell line-derived neuro-
trophic factor (GDNF) for Parkinson’s disease [3,4,24,25].
It has been postulated that perivascular distribution
might result in the immune response seen in some
patients receiving intraputaminal delivery of GDNF, as a
consequence of interaction with resident perivascular
immune cells [9]. The aim of this study was to determine
whether the perivascular distribution of solutes (fluores-
cein-labelled dextrans) delivered by CED into the stria-
tum of rats is affected by the molecular weight of the
infused agent, by co-infusion of vasodilator (to reduce
local vascular pulsation), alteration of infusion rates or
use of a ramping regime. We also wanted to make a pre-
liminary comparison of the distribution of solutes with
that of nanoparticles after CED. The potential implica-
tions of the widespread perivascular distribution of
solutes for future clinical trials are also considered.
Methods
Animal procedures
All in vivo studies were performed in accordance with
University of Bristol animal care policies and with the
authority of appropriate UK Home Office licences.
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Adult male Wistar rats (Charles River, Margate, UK, 225
to 275 g) were anaesthetised with intraperitoneal keta-
mine (Ketaset; 60 mg/kg, Pfizer Animal Health, Sand-
wich, UK) and medetomidine (Dormitor; 0.4 mg/kg,
Pfizer), and then placed in a stereotactic frame (Stoelt-
ing, Illinois, USA). A midline skin incision was made
from glabella to occiput to expose bregma. Bilateral burr
holes were drilled using a 2 mm dental drill. All CED
procedures were performed using a custom-made cathe-
ter with an outer diameter of 0.22 mm and inner dia-
meter of 0.15 mm, composed of fused silica. The
cannula was attached to a 1 ml syringe (Hamilton,
Bonaduz, Switzerland) connected to a rate-controlled
microinfusion pump (World Precision Instruments Inc.,
FL, USA) and the tip placed at stereotactic co-ordinates
derived from the Paxinos and Watson stereotactic rat
brain atlas (0.75 mm anterior and 3 mm lateral to
bregma, depth 4.5 mm), in order to target the striatum
[26]. A total of 6 infusions (bilateral striatal procedures
in 3 animals) were performed for each molecular weight
of dextran per time point (10 min and 3 h). Similarly, a
total of 6 infusions of 20 nm fluospheres were per-
formed per time point.
CED of fluorescein-labelled dextran and fluorescent
nanoparticles
Solutions of 4, 10, 20, 70 or 150 kDa fluorescein-labelled
dextran (Sigma-Aldrich, Gillingham, UK) in artificial cer-
ebrospinal fluid (Torbay Pharmaceuticals, Torbay, UK) at
a concentration of 1 mg/ml were used for solute infu-
sions. Suspensions of 2% carboxylate-modified fluores-
cent nanoparticles of 20 nm diameter (Invitrogen,
Paisley, UK) were used for particulate infusions. Carboxy-
late-modified nanospheres were chosen for their relative
hydrophilicity and net negative charge (characteristics
which are known to confer optimum interstitial distribu-
tion characteristics) [6]. Nanoparticles with 20 nm dia-
meter were selected to allow comparison to 150 kDa
dextran which has an estimated hydrodynamic diameter
of between 16 and 21 nm [27].
A total volume of 5 μl was delivered into the striatum.
CED procedures were performed at an infusion rate of
2.5 μl/min unless otherwise stated. On completion of
CED the cannula was left in situ for 5 min to minimise
reflux, then withdrawn at a rate of 1 mm/min. The
wound was closed with 4/0 Vicryl, and a dose of intra-
muscular buprenorphine was administered (30 μg/kg).
The anaesthetic was reversed with 0.1 mg/kg i.p. atipa-
mezole hydrochloride (Pfizer, Kent, UK) in animals
recovered for 3 h following infusion. Rats were eutha-
nised by anaesthetic overdose with an intraperitoneal
injection of 1 ml pentobarbital (Euthatal; Merial Animal
Health, Harlow, UK), either immediately after removal
of the CED catheter (10 min following termination of
CED) or 3 h after infusion. The 10-min time point
represents the earliest possible time following slow with-
drawal of the CED cannula (which is required to reduce
reflux of infusate). The 3 h time point was selected as
this has previously been shown to be the earliest time at
which perivascular macrophage uptake of tracers is
detectable in studies investigating injection of solutes
into mouse striatum [15]. Following death, animals were
transcardially perfused with 4% paraformaldehyde.
Brains were removed and placed in 4% paraformalde-
hyde for 24 h, then cryoprotected in 30% sucrose.
Immunohistochemistry
Serial cryostat sections of brain, 25 μm thick, were
immunolabelled to identify perivascular tissue elements
in the brain following injection of dextran. Vascular
endothelial cells were labelled with RECA1 monoclonal
antibody (Abcam, Cambridge, UK, 1:300), the laminin
component of vascular basement membranes with a
polyclonal antibody (Sigma-Aldrich, 1:300) and perivas-
cular macrophages with ED1 monoclonal antibody
(Abcam, 1:300). Leptomeningeal macrophages were also
identified by staining with ED1 monoclonal antibody.
Smooth muscle cells in the walls of arteries were identi-
fied by staining for a-smooth muscle actin monoclonal
antibody (Sigma-Aldrich, 1:200). For fluorescence immu-
nohistochemistry, Cy3 (Jackson Laboratories, CA, USA)
or Alexa Fluor 350 (Invitrogen) species-specific second-
ary antibodies were used at a dilution of 1:200. All incu-
bations with primary antibodies were for 18 h at 4°C, and
2 h at room temperature for secondary antibodies.
Co-administration of nimodipine
To investigate the effect of local vasodilatation on the
perivascular distribution of solutes delivered into stria-
tum by CED, solutions of 10 and 150 kDa fluorescein-
labelled dextran were co-infused with the calcium chan-
nel antagonist nimodipine (Bayer Pharmaceutical Cor-
poration, Newbury, UK). An initial pilot study was
performed in order to identify the concentration of
nimodipine required to achieve maximal vasodilatation
of arteries within the striatum. Fluorescein-labelled dex-
tran (10 kDa) was co-infused with nimodipine at con-
centrations of 0.25, 0.5, 1 and 2 mg/ml using the CED
parameters described above. Bilateral infusions of each
nimodipine concentration were performed in a single
animal. Animals were terminated at 10 min following
CED and transcardially perfusion- fixed with 4% paraf-
ormaldehyde. Arteries were identified by staining for a-
smooth muscle actin in 3 striatal sections at 100 μm
intervals. The maximal diameter of smooth muscle
actin-stained blood vessels identified within these sec-
tions was measured and averaged using Stereoinvestiga-
tor software (Microbrightfield, Vermont, USA).
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Investigation of flow rates and ramping regime
To assess whether the infusion flow rate influenced the
perivascular distribution, 10 kDa fluorescein-labelled
dextran was infused at either 1 or 2.5 μl/min. The effect
of ramping (slow stepwise increases in infusion rate) on
the extent of perivascular distribution was also investi-
gated by performing infusions of 10 kDa dextran using
the following ramping regime: 0.5 μl/min for 2 min, 1
μl/min for 1 min, 2.5 μl/min for 30 sec, 5 μl/min until
completion.
Imaging and analysis of distribution
Fluorescent imaging was performed using a Leica
DM5500 microscope (Leica Microsystems, Milton Key-
nes, UK) and digital camera (CX9000 Microbrightfield).
Stereological counts of perivascular macrophages were
undertaken using Stereoinvestigator software (Micro-
brightfield), on sections immunostained for ED1. Co-
localisation of fluorescent dextran with perivascular
macrophages was quantified in 9 high power fields per
striatum (× 20 magnification), on 3 striatal sections at
100 μm intervals, from 3 animals per time point for
each dextran molecular weight. A representative image
of a striatal section used for analysis following CED of
150 kDa dextran is shown in Figure 1A. Cell counts
from 3 striata were then averaged for statistical analysis.
The maximum antero-posterior interstitial spread of
each molecular weight of dextran from the injection site
was estimated from the number of serial sections
demonstrating fluorescence. A qualitative assessment of
the distribution of 4, 10, 20, 70 and 150 kDa fluores-
cein-labelled dextran was also performed by determining
whether dextrans were taken up by ED1-positive lepto-
meningeal macrophages at each time point. Leptome-
ningeal macrophages were differentiated from
perivascular macrophages by their location in the ara-
chnoid membranes on the surface of the brain (Figures
1B, C and 1D).
Figure 1 Widespread interstitial distribution of dextrans and co-localisation with leptomeningeal macrophages following CED. Figure A
shows a low power micrograph of a coronal section through the right striatum of a rat prior to ED1 immunostaining (scale bar = 1 mm).
Labelled are the right lateral ventricle (V), needle track (NT) and interstitial distribution of 150 kDa dextran at 3 h following CED (circled). High
power micrographs of the area within the white box in Figure A illustrate co-localisation of 150 kDa dextran (green) with ED1-positive
leptomeningeal macrophages (red) at 3 h (B, C and D, scale bar = 100 μm).
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Statistical analysis
Statistical analysis was performed using Graphpad Prism
statistical software (Graphpad, CA, USA). One-way ana-
lysis of variance (ANOVA) was performed with Bonfer-
roni adjustment to compare co-localisation of
fluorescein-labelled dextran with perivascular macro-
phages. Results with p < 0.05 were considered
significant.
Results
Convection enhanced delivery of solutes resulted in
widespread perivascular distribution irrespective of
molecular weight
Interstitial and perivascular distribution, as well as peri-
vascular macrophage uptake of 4, 10, 20, 70 and 150
kDa fluorescein-labelled dextran was visible 10 min after
cessation of CED (Figures 1, 2 and 3). At this time
point, a significantly higher proportion of ED1-positive
perivascular macrophages had taken up 4, 10 or 20 kDa
fluorescein-labelled dextran than 150 kDa dextran (p <
0.05). For 4 and 20 kDa dextran, the increase in co-loca-
lisation was highly significant (p < 0.01). However, by 3
h there was no significant difference in perivascular
macrophage uptake between dextrans of any molecular
weight (Figures 4A-F and 4G).
At 10 min following CED, the maximum interstitial
spread of all molecular weights of dextran was greater
than 2000 μm from the striatal injection site in the
antero-posterior plane, as evidenced by the number of
serial sections demonstrating fluorescence. At this early
Figure 2 Co-localisation of solutes with basement membranes. Ten minutes after CED, 10, 70 and 150 kDa dextrans (green) were widely
distributed throughout the perivascular basement membranes of the the striatum (A, D and G). Representative images of perivascular
membranes immunostained for laminin (red) are shown in B, E and H. Figures C, F and I represent merged images. Scale bar = 100 μm.
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time point, all molecular weights of dextran were seen
to co-localise with perivascular macrophages within the
striatum. Co-localisation of 4, 10 and 20 kDa dextran
with ED1-positive leptomeningeal macrophages was also
visible at the 10 min time-point. In contrast, co-localisa-
tion of 70 and 150 kDa dextrans with leptomeningeal
macrophages was only visible at 3 h. By 3 h following
CED, 4, 10 and 20 kDa dextran had been cleared from
the parenchyma, whilst 70 and 150 kDa dextrans
remained visible in the interstitial spaces of the striatum.
A summary of the locations of each dextran at 10 min
and 3 h following CED is shown in table 1.
Co-infusion with nimodipine did not reduce perivascular
distribution
The pilot study demonstrated that co-infusion of
nimopidine resulted in increasing arterial vasodilation
at concentrations of 0.25, 0.5 and 1 mg/ml. However,
no additional increase in maximal arterial diameter
was demonstrated with a dose of 2 mg/ml. Subsequent
Figure 3 Perivascular distribution of solutes external to vascular endothelium. Ten minutes after CED 10, 70 and 150 kDa dextrans (green)
were seen in the perivascular spaces external to the vascular endothelium (A, D and G). Representative images of vascular endothelial cells
immunostained for RECA1 (red) are shown in B, E and H. Figures C, F and I represent merged images. Scale bar = 100 μm.
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CED procedures were therefore performed at a nimo-
pidine concentration of 1 mg/ml. Widespread perivas-
cular distribution and uptake by perivascular
macrophages of 10 and 150 kDa dextran was visible
despite obvious local vasodilatation (Figure 5A and
5B). There was no significant difference in uptake of
either 10 or 150 kDa dextran by perivascular
macrophages when the dextrans were infused with or
without nimodipine (Figure 5C).
Slow infusion rates and ramping did not prevent
perivascular distribution
Widespread perivascular distribution of 10 kDa dextran
was visible 10 min after cessation of CED whether the
Figure 4 Co-localisation of fluorescein-labelled dextran with ED1-positive perivascular macrophages. Ten minutes after CED there was
widespread co-localisation of fluorescein-labelled dextran (green) with perivascular macrophages immunostained for ED1 (red). Representative
images from animals infused with 10 and 150 kDa dextran are shown in A-F. Scale bar = 100 μm. Stereological cell counts demonstrated
significantly higher co-localisation of 4, 10 and 20 kDa dextrans than 150 kDa dextran, 10 min after CED. For 4 and 20 kDa dextran, the increase
in co-localisation was highly significant (*p < 0.01). However by 3 h there were no significant differences in uptake (figure G). Each histogram bar
represents mean cell counts from 3 striata +/- S.D.
Table 1 Distribution of dextran following CED into rat striatum
Molecular weight 4 kDa 10 kDa 20 kDa 70 kDa 150 kDa
Time point 10 min 3 h 10 min 3 h 10 min 3 h 10 min 3 h 10 min 3 h
Interstitial spaces + - + - + - + + + +
Perivascular macrophages + + + + + + + + + +
Leptomeningeal macrophages + + + + + + - + - +
+ present, - absent
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dextran was infused at 1 or 2.5 μl/min. Use of a ramp-
ing regime did not prevent perivascular distribution. No
significant difference in uptake by perivascular ED1-
positive cells was demonstrated when 10 kDa dextran
was infused at 1 or 2.5 μl/min, or when a ramping
regime was used (Figure 6).
CED of fluorescent nanoparticles
Our preliminary studies of CED of 20 nm fluorescent
nanoparticles indicate that particles of this size co-loca-
lise with perivascular basement membranes throughout
the striatum by 10 min following CED but, unlike solu-
ble dextrans, are not taken up by perivascular macro-
phages at either 10 min or 3 h (Figure 7).
Discussion
Convection-enhanced delivery has emerged as a promis-
ing technique for direct drug delivery to the brain,
bypassing the blood brain barrier and enabling
distribution of therapeutic agents throughout large
volumes of brain parenchyma. In this study we sought
to determine whether perivascular distribution is likely
to be an inevitable consequence of CED of solutes, and
also to determine whether the extent of perivascular dis-
tribution is affected by the molecular weight of the
solute, co-infusion of vasodilator, the rate of infusion
and use of a ramping regime.
Whilst the evidence for the mechanisms which drive
perivascular fluid flow in the brain remains controver-
sial, drainage of endogenous solutes along perivascular
basement membranes is thought to be a consequence of
bulk flow rather than simple diffusion [28]. A number
of studies involving injection of tracers into the brain
have demonstrated rapid and widespread distribution
throughout the perivascular spaces consistent with bulk
flow [14,29,11]. Consequently, the molecular weight of
solutes might not be expected to affect the rate of peri-
vascular drainage. In this study, significantly more 4, 10
Figure 5 Co-infusion of 10 and 150 kDa dextran with nimodipine. Co-infusion of the vasodilator nimodipine did not prevent perivascular
spread of solutes. Representative images at 10 min following CED of 150 kDa dextran (green) demonstrating widespread interstitial and
perivascular solute are shown in figures A and B. Stereological comparisons of ED1 perivascular macrophage uptake of 10 and 150 kDa dextran
with and without nimodipine did not reveal any statistically significant differences (figure C). Each histogram bar represents mean cell counts
from 3 striata +/- S.D. Scale bars in both A and B = 100 μm.
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and 20 kDa dextran than 150 kDa dextran had been
taken up by perivascular macrophages 10 min following
CED. Furthermore, co-localisation of 70 and 150 kDa
dextran with leptomeningeal macrophages was only visi-
ble at 3 h. It seems most likely that the smaller molecu-
lar weight dextrans are simply taken up more efficiently
by the macrophages, but we cannot exclude the possibi-
lity that the difference reflects an influence of the mole-
cular weight of the solute on the rate of perivascular
spread after CED, and consequently the timing of
uptake by perivascular macrophages. By 3 h there was
no significant difference in the extent of perivascular
macrophage uptake of solutes of any molecular weight,
perhaps because bulk flow takes over as the predomi-
nant driving force behind perivascular drainage once the
pressure gradient is removed.
We also sought to determine whether local vasodilata-
tion might reduce the extent of or prevent perivascular
distribution of solutes. In a study incorporating mathema-
tical modelling of perivascular drainage, Schley et al. [17]
postulated that changes in the calibre of blood vessels dur-
ing each pulse cycle might alter the width of the perivascu-
lar spaces thereby providing the motive force for
perivascular drainage. In this model, perivascular drainage
occurs mainly during periods of vasoconstriction, as a
reduction in vessel calibre acts to “open” the perivascular
spaces. The authors suggested that a reduction in pulse
amplitude, as occurs in ageing, slows the clearance of
endogenous solutes (such as Ab peptide, resulting in peri-
vascular deposition and cerebral amyloid angiopathy). In
this study we induced local vasodilatation by co-infusing
with nimodipine. By causing prolonged smooth muscle
relaxation, we sought to determine whether co-infusion of
nimodipine might reduce the perivascular distribution of
solutes by preventing vasoconstriction in the period imme-
diately following CED. However, this strategy did not pre-
vent extensive perivascular spread or reduce the amount
of 10 or 150 kDa dextran taken up by perivascular macro-
phages 10 min or 3 h following CED.
The use of slow stepwise increases in infusion rate
(ramping) has been investigated in pre-clinical studies,
with the aim of increasing the volume of distribution of
drugs delivered by CED and to mitigate reflux [30].
Although the exact mechanisms by which ramping pro-
motes interstitial drug distribution over reflux are not
fully understood, we can hypothesise that slow stepwise
increases in infusion rate might act to mechanically
increase the effective pore size of the interstitial spaces
of the brain. By increasing the extracellular porosity of
the brain parenchyma, ramping might act to reduce the
resistance to fluid flow within the interstitial spaces. In
our study, there was no difference in perivascular spread
or the amount of uptake of 10 kDa dextran by perivas-
cular macrophages when the infusion rate was varied
from 1 to 2.5 μl/min, or gradually increased from 0.5 to
5 μl/min. For CED to be effectively translated to clinical
trials, it will be necessary to use flow rates within this
range for therapeutic agents to be distributed through
clinically relevant volumes of brain tissue over a time
period which is acceptable to patients [31]. In our forth-
coming clinical trial of intraputaminal CED of GDNF
for Parkinson’s disease, we intend to use flow rates of
up to 5 μl/min in order to limit the period of infusion
to approximately two hours.
This study suggests that widespread perivascular dis-
tribution and interaction with perivascular macrophages
is likely to be an inevitable consequence of CED of
solutes irrespective of their molecular weight, co-infu-
sion with vasodilators, and use of either slow infusion
rates or ramping regimes. Convection-enhanced delivery
of viral vectors has previously been shown to result in
transfection of perivascular macrophages, suggesting
that the interaction with perivascular macrophages seen
in this study is not a property of dextrans alone [31].
The recent application of advances in nanoparticle tech-
nology to CED raises the question of whether this con-
clusion is applicable to particulate infusates [32]. Our
preliminary studies suggest that whilst CED of 20 nm
nanoparticles also results in perivascular distribution,
their interaction with perivascular macrophages may dif-
fer from solutes. Further studies are needed to investi-
gate the influence of nanoparticle size and charge in
greater detail.
There is evidence from pre-clinical studies in both rats
and mice that the perivascular spaces of the brain are
Figure 6 CED using slow infusion rates and ramping regime.
Slow infusion of 10 kDa dextran at 1 μl/min or use of a ramping
regime did not prevent perivascular distribution. Stereological
comparisons revealed no significant difference in uptake of 10 kDa
Dextran by ED1-positive perivascular macrophages when infused at
1 or 2.5 μl/min or when a ramping regime was used. Each
histogram bar represents mean cell counts from 3 striata +/- S.D.
Barua et al. Fluids and Barriers of the CNS 2012, 9:2
http://www.fluidsbarrierscns.com/content/9/1/2
Page 9 of 12
Figure 7 CED of 20 nm fluorescent particles. Ten minutes following CED, 20 nm fluospheres (green, figure A) were seen to co-localise with
perivascular basement membranes immunostained for laminin (blue, figure B). Appearances at 3 h following CED showed similar co-localisation
without evidence of uptake of fluospheres by perivascular macrophages (figures D and E). Figures C and F represent merged images. Scale bar =
100 μm.
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under immune surveillance by cells of monocyte/macro-
phage lineage which undergo continuous turn-over
[33,34]. These perivascular immune cells have been
implicated in neuroinflammatory processes related to
cerebral amyloid angiopathy (CAA), Alzheimer’s disease
(AD) and multiple sclerosis [35-37]. Hawkes et al.
demonstrated that depletion of perivascular macro-
phages in a transgenic mouse model of AD resulted in
elevation of vascular Ab level [35]. For disease processes
involving the perivascular pathways such as CAA and
AD, convection-enhanced delivery might offer a method
of directing therapeutic agents to both interstitial and
perivascular spaces of the brain.
Conversely, perivascular distribution of some therapies
delivered by CED might be undesirable in clinical trials
for a number of reasons. Uptake of therapeutic proteins
by perivascular macrophages might elicit a neutralising
or damaging immune response (which may have con-
tributed to the lack of efficacy seen in clinical trials of
GDNF delivery to the putamen [9]). The perivascular
drainage of drugs delivered into deep grey matter struc-
tures might also result in distribution into the subarach-
noid space. In a clinical context, this could result in
unwanted side-effects such as nerve root irritation.
Furthermore, widespread perivascular distribution of
cytotoxic chemotherapies might significantly reduce (or
eliminate) the resident perivascular immune cell popula-
tion, resulting in impaired handling of toxic metabolites
and dampening of the innate immune response to
tumour cells [35].
Conclusions
This study suggests that CED of soluble pharmacological
agents is likely to result in perivascular distribution and
interaction with perivascular macrophages, irrespective
of the molecular weight of the therapeutic agent or the
infusion regime used. The potential consequences of
widespread perivascular distribution of therapeutic
agents, and in particular cytotoxic chemotherapies,
delivered by CED must be carefully considered to ensure
safe and effective translation to clinical trials.
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